| Identification | Back Directory | [Name]
1H-Imidazole-2-carboxylic acid, 5,5-di-(8Z)-8-heptadecen-1-yl-2,5-dihydro-1-[3-(1-pyrrolidinyl)propyl]-, ethyl ester | [CAS]
2412492-07-8 | [Synonyms]
A2-Iso5-2DC18
1H-Imidazole-2-carboxylic acid, 5,5-di-(8Z)-8-heptadecen-1-yl-2,5-dihydro-1-[3-(1-pyrrolidinyl)propyl]-, ethyl ester | [Molecular Formula]
C47H87N3O2 | [MOL File]
2412492-07-8.mol | [Molecular Weight]
726.21 |
| Chemical Properties | Back Directory | [Boiling point ]
746.3±60.0 °C(Predicted) | [density ]
0.95±0.1 g/cm3(Predicted) | [form ]
Liquid | [pka]
10.26±0.20(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
A2-Iso5-2DC18 is a dihydroimidazole-linked lipid, served as potent mRNA delivery vehicle. A2-Iso5-2DC18 can be used for antitumor research, including B16F10 melanoma.[1]. | [in vivo]
A2-Iso5-2DC18, loaded with mLuc or Cre-recombinase mRNA LNPs (mCre), (0.1 mg/kg and 0.5 mg/kg; s.c.; once a week, for 2 weeks) transfects central antigen presenting cells (APCs) in A14/Cre mRNA mouse model[1].
A2-Iso5-2DC18 loaded with OVA mRNA (mOVA) vaccine, (15?μg mOVA per mouse; s.c.; twice dose, once every 5 d) induces a significantly high antigen-specific cytotoxic T lymphocyte (CTL) response, in parallel with robust IFN-? secretion in B16F10 mouse melanoma model[1].
| Animal Model: | A14/Cre mRNA mouse model (female B6 mice)[1] | | Dosage: | Loaded with Cre-recombinase mRNA LNPs (mCre); 0.1 mg/kg and 0.5 mg/kg | | Administration: | Subcutaneous injection; 3 weeks | | Result: | Induced protein expression in the local injection site and the draining lymph nodes and transfected central antigen presenting cells (APCs) including macrophages/monocytes (CD11b+) and dendritic cells (CD11c+) in mice.
|
| Animal Model: | Ovalbumin (OVA)-expressing B16F10 mouse melanoma model[1] | | Dosage: | Loaded with OVA mRNA (mOVA) vaccine; 15?μg mOVA per mouse | | Administration: | Subcutaneous injection; once per week for the first two weeks; 3 weeks continuous observation | | Result: | Significantly decreased tumor volume of B16-OVA melanoma and improved overall survival in mice.
Increased the number of systemic and tumor-infiltrating antigen-specific T?cells dramatically (20–30-fold). |
| [References]
[1] Miao L, et al. Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat Biotechnol. 2019 Oct;37(10):1174-1185. DOI:10.1038/s41587-019-0247-3 |
|
| Company Name: |
DC Chemicals
|
| Tel: |
021-58447131 13564518121 |
| Website: |
www.chemicalbook.com/showsupplierproductslist927327/0_en.htm |
|